Federal Register / Vol. 88, No. 247 / Wednesday, December 27, 2023 / Notices 89461 

Extramural Activities, NIDCD, NIH, 6001 

Executive Blvd., Bethesda, MD 20892, 301– 

496–8683, shimk@nidcd.nih.gov. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel; Chemical 

Senses Fellowship Review. 

Date: February 8, 2024. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Shiguang Yang, DVM, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, NIDCD, NIH, 6001 

Executive Blvd., Room 8349, Bethesda, MD 

20892, 301–496–8683, yangshi@

nidcd.nih.gov. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel; Voice 

Speech and Language Fellowship Review. 

Date: February 9, 2024. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Sonia Elena Nanescu, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, NIDCD, NIH, 6001 

Executive Blvd., Suite 8300, Bethesda, MD 

20892, (301) 496–8683, sonia.nanescu@

nih.gov. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel; Hearing 

and Balance Fellowship Review. 

Date: February 13, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Kausik Ray, Ph.D., 

Scientific Review Officer, National Institute 

on Deafness and Other Communication 

Disorders, National Institutes of Health, 6001 

Executive Blvd., Rockville, MD 20852, 301– 

402–3587. rayk@nidcd.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: December 21, 2023. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–28572 Filed 12–26–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Risk, Prevention and 

Health Behavior Integrated Review Group; 

Biobehavioral Medicine and Health 

Outcomes Study Section. 

Date: January 29–30, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Mark A. Vosvick, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3110, 

Bethesda, MD 20892, (301) 402–4128, 

mark.vosvick@nih.gov. 

Name of Committee: Cell Biology 

Integrated Review Group; Cellular Signaling 

and Regulatory Systems Study Section. 

Date: January 29–30, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: David Balasundaram, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5189, 

MSC 7840, Bethesda, MD 20892, 301–435– 

1022, balasundaramd@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–OD– 

23–051 Emergency Award: RADx-UP 

Dissemination and Implementation (D&I) 

Research on COVID–19 Testing Interventions 

among Underserved and Vulnerable 

Populations. 

Date: January 31, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jessica Bellinger, Ph.D., 

Scientific Review Administrator, Center for 

Scientific of Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3158, 

Bethesda, MD 20892, 301–827–4446, 

bellingerjd@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: December 21, 2023. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–28531 Filed 12–26–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government Owned Inventions 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

directed to a T cell receptor (TCR) that 

specifically targets the Kita-Kyushu 

Lung Cancer Antigen 1 (KK–LC–1). This 

TCR may be used to develop novel 

immunotherapies against several 

common and aggressive epithelial 

cancers. It may also be possible to use 

portions of the KK–LC–1 TCR in 

chimeric proteins for cancer therapy 

and/or for antigen detection assays. This 

technology was discovered and is being 

developed by the National Cancer 

Institute (NCI). The NCI is currently 

seeking a licensee and/or collaborator to 

further develop this technology. 

FOR FURTHER INFORMATION CONTACT: 

Inquiries related to this licensing and 

collaboration opportunity should be 

directed to: Suna Gulay French, 

Technology Transfer Manager, NCI 

Technology Transfer Center, 9609 

Medical Center Drive, RM 1E530 MSC 

9702, Bethesda, MD 20892–9702 (for 

business mail), Rockville, MD 20850– 

9702; Telephone: (240) 276–5530; 

Facsimile: (240) 276–5504; Email: 

suna.gulay@nih.gov. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of 

unpublished information related to this 

invention. 

SUPPLEMENTARY INFORMATION: The 

following patent applications are 

available for licensing and/or 

collaboration under a Cooperative 

Research and Development Agreement 

(CRADA): 

1. U.S. Provisional Application No. 

62/327,529; 


ddrumheller on DSK120RN23PROD with NOTICES1
89462 Federal Register / Vol. 88, No. 247 / Wednesday, December 27, 2023 / Notices 

2. PCT Application No. PCT/US17/ 

027865; 

3. U.S. Patent No. 11,352,410; 

4. Australia Patent Application No. 

2017258745; 

5. Canada Patent Application No. 

3021898; and 

6. European Patent No. 17733120.4, 

validated in Switzerland, Germany, 

Belgium, Denmark, Spain, Finland, 

France, United Kingdom, Ireland, Italy, 

The Netherlands, Norway, Sweden. 

Achieving expeditious 

commercialization of federally funded 

research and development is consistent 

with the goals of the Bayh-Dole Act, 

codified as 35 U.S.C. 200–212. 

Background and Description of 

Technology 

Metastatic cancers are the cause of up 

to 90% of cancer deaths, yet few 

treatment options exist for patients with 

metastatic disease. Adoptive transfer of 

T cells that express tumor-reactive Tcell receptors (TCRs) has been shown to 

mediate regression of metastatic cancers 

in some patients. However, 

identification of antigens that are 

expressed solely by cancer cells and not 

normal tissues has been a major 

challenge for the development of TCRbased immunotherapies. Researchers at 

the National Cancer Institute (NCI) have 

developed a TCR that specifically 

targets the Kita-Kyushu Lung Cancer 

Antigen 1 (KK–LC–1) 52–60 epitope. 

KK–LC–1 antigen (encoded by the CT83 

gene) is highly expressed in several 

common and aggressive epithelial tumor 

types. Importantly, KK–LC–1 is 

expressed at very low levels in normal 

tissues and is not expressed in lifeessential tissues. This expression profile 

makes KK–LC–1 an attractive target for 

TCR-based anti-cancer therapies. This 

TCR may be used to genetically modify 

peripheral blood lymphocytes from 

eligible patients. After expansion, these 

genetically modified lymphocytes can 

be used to treat patients. This 

technology is currently being evaluated 

in clinical trials at the NCI and at 

Rutgers Cancer Institute of New Jersey. 

Potential Commercial Applications 

T cell receptor (TCR)-based 

immunotherapies and/or therapeutic 

products against several common and 

aggressive epithelial tumor types. 

Competitive Advantages 

—This TCR has been preclinically 

validated and is currently being 

evaluated in the clinic; 

—Differential expression profile of KK– 

LC–1 in cancers versus normal tissues 

suggests that therapy with a specific 

KK–LC–1 TCR would be cancerspecific and would not damage lifeessential tissues; 

—Thousands of cancer patients each 

year with otherwise untreatable 

disease may be eligible for treatment 

with this TCR. 

Development Stage 

Clinical development. 

Dated: December 20, 2023. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2023–28481 Filed 12–26–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Brian Bailey at 301–201–9217, 240– 

669–5128, or bbailey@mail.nih.gov. 

Licensing information may be obtained 

by communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852: tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Immortalized Rhesus macaque Bcl-6/ 

Bcl-xL Stable B Cell Lines as Tools for 

HIV Antibody Discovery. 

Description of Technology 

Scientists at NIAID have developed 

two immortalized stable B cell lines 

from rhesus macaques that can have 

value as research tools for the discovery 

of neutralizing antibodies of simian 

origin against HIV and that may have 

value in the development of an HIV 

vaccine. These B cell lines encode 

human Bcl-6 and Bcl-xL proteins, which 

are major regulators of apoptosis. These 

B cell lines are derived from the lymph 

node of a rhesus macaque (RM) that was 

infected with SHIV.CH505. It was 

discovered that, unlike in humans, 

rhesus macaque B cells from lymph 

nodes are more effectively immortalized 

than B cells from Peripheral Blood 

Mononuclear Cells (PBMCs). 

After sample collection and 

cryopreservation, pro B cells were 

isolated, sorted by flow cytometry for 

populations of interest, then activated 

with CD40 ligand and RM IL–2 followed 

by transduction with a retroviral vector 

encoding Bcl-6, Bcl-xL, and green 

fluorescent protein (GFL), thereby 

creating immortalized clonal lines. Two 

clones were down selected for their in 

vitro neutralizing ability against HIV 

pseudovirus CH505. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Bcl-6 and Bc-xL immortalization is 

a valuable and flexible tool for HIV 

antibody discovery in rhesus macaques. 

• Contributes to pre-clinical 

therapeutic and vaccine development. 

Competitive Advantages 

• The cell lines have been 

characterized and are readily 

expandable for bulk applications as well 

as for making high-throughput clonal 

cultures with or without antigen probes 

in 384-well plates. 

Development Stage 

• Research Materials 

Inventors: Jakob Samsel, Ph.D.; 

Richard Koup, MD; Kristin Boswell, 

Ph.D.; all of NIAID. 

Publications: Samsel, Jakob, et al. 

‘‘Rhesus macaque bcl-6/bcl-XL B cell 

immortalization: Discovery of HIV–1 

neutralizing antibodies from lymph 

node.’’ Journal of Immunological 

Methods, vol. 516, May 2023, p. 113445, 

https://doi.org/10.1016/ 

j.jim.2023.113445. 

Intellectual Property: HHS Reference 

No. E–196–2023–0–EIR–00. 

Licensing Contact: To license this 

technology, please contact Brian Bailey 

at 301–201–9217, 240–669–5128, or 

bbailey@mail.nih.gov., and reference E– 

196–2023. 


ddrumheller on DSK120RN23PROD with NOTICES1